Clinical trials: sponsored by Celgene
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
- Conditions
- Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III
- Trial name
- CRISP (NCT02622581)
- Testing
- data collection
- Where
- Germany
- Volunteers
- 14,500 people
- Sponsor
- AIO-Studien-gGmbH
Multiple Myeloma
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment.
- Trial name
- NCT07624513
- Testing
- Isatuximab, Iberdomide, Bortezomib (B)
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
- Trial name
- REGISTEM (NCT02819882)
- Testing
- No intervention
- Where
- 40 sites in Spain
- Volunteers
- 1,867 people
- Sponsor
- Spanish Breast Cancer Research Group
Smoldering Multiple Myeloma
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: Lenalidomide Citarinostat (CC-96241) PVX-410
- Trial name
- NCT02886065
- Testing
- Hiltonol, Citarinostat, Lenalidomide
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Myeloma, Multiple Myeloma
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
- Conditions
- Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT06518551
- Testing
- Elotuzumab, Iberdomide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Omar Nadeem, MD
Agitation, Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
- Trial name
- NCT06808984
- Testing
- BMS-986368
- Where
- 77 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Celgene
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 58 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory…
- Trial name
- SUCCESSOR-1 (NCT05519085)
- Testing
- mezigdomide, Pomalidomide, Bortezomib
- Where
- 266 sites in United States, Argentina and 27 more
- Volunteers
- 810 people
- Sponsor
- Celgene
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Acute Myelogenous Leukemia
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML).
- Trial name
- NCT03059485
- Testing
- DC/AML Fusion Vaccine, Observation
- Where
- 4 sites in United States
- Volunteers
- 82 people
- Sponsor
- Beth Israel Deaconess Medical Center
MDS, Myelodysplastic Syndromes
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
- Trial name
- NCT05181735
- Testing
- Luspatercept Injection [Reblozyl], Eprex
- Where
- 41 sites in France, Italy
- Volunteers
- 150 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Multiple Myeloma
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to see whether pomalidomide (also known as Pomalyst) reduces the number of myeloma cells in the bones, and to see what is the best way to use pomalidomide in patients with myeloma.
- Trial name
- NCT01745588
- Testing
- Pomalidomide, stem cell, Dexamethasone
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement…
- Conditions
- B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT02992522
- Testing
- Lenalidomide, Obinutuzumab, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Beth Christian
Healthy Volunteers
A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants
The purpose of this study is to evaluate the relative bioavailability of irafamdastat and to assess food-effect on the pharmacokinetics (PK) of irafamdastat ODT in healthy adult participants.
- Trial name
- NCT07837115
- Testing
- Irafamdastat
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Neoplasms
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene…
- Trial name
- NCT03435796
- Testing
- Gene-modified (GM) T cell therapy
- Where
- 222 sites in United States, Australia and 20 more
- Volunteers
- 1,541 people
- Sponsor
- Celgene
Systemic Sclerosis
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
- Trial name
- Breakfree-SSc (NCT07335562)
- Testing
- BMS-986353, Fludarabine, Cyclophosphamide
- Where
- 56 sites in United States, Belgium and 8 more
- Volunteers
- 92 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed or Refractory Multiple Myeloma (RRMM)
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
- Trial name
- NCT06615479
- Testing
- BMS-986393, Cyclophosphamide, Fludarabine
- Where
- 141 sites in United States, Argentina and 29 more
- Volunteers
- 440 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Central Nervous System Neoplasm, Cranial Nerve Disorder
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system.
- Conditions
- Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT03270059
- Testing
- Ferumoxytol, Gadolinium, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- OHSU Knight Cancer Institute
Eosinophilic Gastroenteritis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.
- Trial name
- NCT05214768
- Testing
- CC-93538
- Where
- 25 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT03383575
- Testing
- Azacitidine, Enasidenib, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center